DANBURY, Conn.--(BUSINESS WIRE)--Biodel Inc. (Nasdaq: BIOD) will issue its fiscal first quarter 2009 financial results on February 5, 2009. The company will also discuss the top line results of its study testing the bioequivalence of the 25 IU two part formulation and 100 IU one part liquid formulation of VIAject(TM) in patients with Type 1 diabetes. Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress.
